FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224256303> ?p ?o ?g. }

• W4224256303 endingPage "1747" @default.
• W4224256303 startingPage "1736" @default.
• W4224256303 abstract "Objective Rett syndrome (RTT), commonly caused by methyl-CpG-binding protein 2 (MECP2) pathogenic variants, has many comorbidities. Fifty to ninety percent of children with RTT have epilepsy, which is often drug-resistant. Cannabidivarin (CBDV), a non-hallucinogenic phytocannabinoid, has shown benefit in MECP2 animal models. This phase 1 trial assessed the safety and tolerability of CBDV in female children with RTT and drug-resistant epilepsy, as well as the effect on mean monthly seizure frequency (MMSF), the electroencephalogram (EEG), and non-epilepsy comorbid symptoms. Methods Five female children with drug-resistant epilepsy and a pathogenic MECP2 variant were enrolled. Baseline clinical and laboratory assessments, including monthly seizure frequency, were recorded. CBDV oral solution (50 mg/ml) was prescribed and titrated to 10 mg/kg/day. Data collected included pharmacokinetics, seizure type and frequency, adverse events, EEG, and responses to the Rett Syndrome Behaviour Questionnaire and Rett Syndrome Symptom Severity Index, and were compared to baseline data. Results All five children reached the maximum CBDV dose of 10 mg/kg/day and had a reduction in MMSF (median = 79% reduction). Three children had MMSF reduction > 75%. This corresponded to an overall reduction in seizure frequency from 32 to 7.2 seizures per month. Ninety-one percent of adverse events were mild or moderate, and none required drug withdrawal. Sixty-two percent were judged to be unrelated to CBDV. Thirty-one percent of adverse events were identified as possibly related, of which nearly all were mild, and the remainder were later assessed as RTT symptoms. Hypersomnolence and drooling were identified as related to CBDV. No serious adverse events reported were related to CBDV. No significant change was noted in EEG or non-epilepsy-related symptoms of RTT. Significance A dose of 10 mg/kg/day of CBDV is safe and well tolerated in a pediatric RTT cohort and suggests improved seizure control in children with MECP2-related RTT." @default.
• W4224256303 created "2022-04-26" @default.
• W4224256303 creator A5003943325 @default.
• W4224256303 creator A5010506176 @default.
• W4224256303 creator A5026363319 @default.
• W4224256303 creator A5044124013 @default.
• W4224256303 creator A5044346505 @default.
• W4224256303 creator A5052493334 @default.
• W4224256303 creator A5056481563 @default.
• W4224256303 creator A5091830023 @default.
• W4224256303 date "2022-04-20" @default.
• W4224256303 modified "2023-10-11" @default.
• W4224256303 title "Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial" @default.
• W4224256303 cites W1555923997 @default.
• W4224256303 cites W1566787323 @default.
• W4224256303 cites W1742914638 @default.
• W4224256303 cites W1920696238 @default.
• W4224256303 cites W2000692938 @default.
• W4224256303 cites W2017448309 @default.
• W4224256303 cites W2063840478 @default.
• W4224256303 cites W2066619092 @default.
• W4224256303 cites W2075999647 @default.
• W4224256303 cites W2076878058 @default.
• W4224256303 cites W2079860184 @default.
• W4224256303 cites W2081618880 @default.
• W4224256303 cites W2087381327 @default.
• W4224256303 cites W2094841633 @default.
• W4224256303 cites W2107812784 @default.
• W4224256303 cites W2119071913 @default.
• W4224256303 cites W2123678721 @default.
• W4224256303 cites W2154057943 @default.
• W4224256303 cites W2408610698 @default.
• W4224256303 cites W2514926883 @default.
• W4224256303 cites W2565914894 @default.
• W4224256303 cites W2591684005 @default.
• W4224256303 cites W2768618620 @default.
• W4224256303 cites W2790342739 @default.
• W4224256303 cites W2883591107 @default.
• W4224256303 cites W2892791881 @default.
• W4224256303 cites W2910835842 @default.
• W4224256303 cites W2926987093 @default.
• W4224256303 cites W2945913151 @default.
• W4224256303 cites W2950842908 @default.
• W4224256303 cites W3005082022 @default.
• W4224256303 cites W3019063370 @default.
• W4224256303 cites W3031230406 @default.
• W4224256303 cites W3038365639 @default.
• W4224256303 cites W3130793960 @default.
• W4224256303 cites W3157300771 @default.
• W4224256303 cites W3175962986 @default.
• W4224256303 cites W3185865922 @default.
• W4224256303 cites W4224256303 @default.
• W4224256303 doi "https://doi.org/10.1111/epi.17247" @default.
• W4224256303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35364618" @default.
• W4224256303 hasPublicationYear "2022" @default.
• W4224256303 type Work @default.
• W4224256303 citedByCount "9" @default.
• W4224256303 countsByYear W42242563032022 @default.
• W4224256303 countsByYear W42242563032023 @default.
• W4224256303 crossrefType "journal-article" @default.
• W4224256303 hasAuthorship W4224256303A5003943325 @default.
• W4224256303 hasAuthorship W4224256303A5010506176 @default.
• W4224256303 hasAuthorship W4224256303A5026363319 @default.
• W4224256303 hasAuthorship W4224256303A5044124013 @default.
• W4224256303 hasAuthorship W4224256303A5044346505 @default.
• W4224256303 hasAuthorship W4224256303A5052493334 @default.
• W4224256303 hasAuthorship W4224256303A5056481563 @default.
• W4224256303 hasAuthorship W4224256303A5091830023 @default.
• W4224256303 hasBestOaLocation W42242563032 @default.
• W4224256303 hasConcept C104317684 @default.
• W4224256303 hasConcept C118552586 @default.
• W4224256303 hasConcept C126322002 @default.
• W4224256303 hasConcept C127716648 @default.
• W4224256303 hasConcept C185592680 @default.
• W4224256303 hasConcept C187212893 @default.
• W4224256303 hasConcept C197934379 @default.
• W4224256303 hasConcept C2777543196 @default.
• W4224256303 hasConcept C2778186239 @default.
• W4224256303 hasConcept C2778375690 @default.
• W4224256303 hasConcept C2778863441 @default.
• W4224256303 hasConcept C2779307984 @default.
• W4224256303 hasConcept C42219234 @default.
• W4224256303 hasConcept C535046627 @default.
• W4224256303 hasConcept C55493867 @default.
• W4224256303 hasConcept C71924100 @default.
• W4224256303 hasConceptScore W4224256303C104317684 @default.
• W4224256303 hasConceptScore W4224256303C118552586 @default.
• W4224256303 hasConceptScore W4224256303C126322002 @default.
• W4224256303 hasConceptScore W4224256303C127716648 @default.
• W4224256303 hasConceptScore W4224256303C185592680 @default.
• W4224256303 hasConceptScore W4224256303C187212893 @default.
• W4224256303 hasConceptScore W4224256303C197934379 @default.
• W4224256303 hasConceptScore W4224256303C2777543196 @default.
• W4224256303 hasConceptScore W4224256303C2778186239 @default.
• W4224256303 hasConceptScore W4224256303C2778375690 @default.
• W4224256303 hasConceptScore W4224256303C2778863441 @default.
• W4224256303 hasConceptScore W4224256303C2779307984 @default.
• W4224256303 hasConceptScore W4224256303C42219234 @default.

• next